Platelet reactivity in depressed patients treated with paroxetine: Preliminary findings

Dominique Musselman, Ulla M. Marzec, Amita Manatunga, Suzanne Penna, Andrea Reemsnyder, Bettina T. Knight, Aimee Baron, Stephen R. Hanson, Charles Nemeroff

Research output: Contribution to journalArticle

180 Citations (Scopus)

Abstract

Background: Alterations in platelet reactivity have been previously posited to underlie the increased vulnerability of patients with depression to ischemic heart disease (IHD). The present study sought to determine whether the increased platelet reactivity associated with major depression is reduced after antidepressant treatment. Methods: Patients diagnosed as having DSM-IV major depression (n = 15) (mean age, 37±7 years; range, 23-48 years) and 12 normal comparison subjects (mean age, 36±7; range, 23-48 years) were recruited. None of the controls or depressed group had evidence of IHD; 10 of 15 patients who were depressed had 1 or more traditional IHD risk factors. In vivo platelet activation, secretion, and dose-response aggregation of the controls and patients was measured after overnight bedrest under basal conditions, and after a mild exercise challenge. After 6 weeks of open-label treatment with the selective serotonin reuptake inhibitor paroxetine (20 mg/d), the patients with depression were readmitted and procedures of the first General Clinical Research Center admission repeated. Results: In comparison with the control group, the depressed group exhibited greater procoagulant activity as detected by increased platelet binding of the monoclonal antibodies anti-ligand-induced binding site and GA6, and increased plasma concentrations of platelet factor 4 under basal conditions. After paroxetine treatment, the patients with depression exhibited significant reductions in all 3 parameters. Conclusions: Normalization of platelet activation is associated with paroxetine treatment of patients with depression. Because this study design did not allow for the determination of whether this effect of paroxetine on platelet function is caused by a direct effect of the drug or placebo or, alternatively, because of recovery from depression, studies containing a placebo and/or psychotherapy treatment arm may resolve this issue.

Original languageEnglish
Pages (from-to)875-882
Number of pages8
JournalArchives of General Psychiatry
Volume57
Issue number9
StatePublished - Sep 19 2000
Externally publishedYes

Fingerprint

Paroxetine
Blood Platelets
Depression
Myocardial Ischemia
Platelet Activation
Placebos
Platelet Factor 4
Therapeutics
Bed Rest
Serotonin Uptake Inhibitors
Psychotherapy
Diagnostic and Statistical Manual of Mental Disorders
Antidepressive Agents
Binding Sites
Monoclonal Antibodies
Exercise
Ligands
Control Groups
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Musselman, D., Marzec, U. M., Manatunga, A., Penna, S., Reemsnyder, A., Knight, B. T., ... Nemeroff, C. (2000). Platelet reactivity in depressed patients treated with paroxetine: Preliminary findings. Archives of General Psychiatry, 57(9), 875-882.

Platelet reactivity in depressed patients treated with paroxetine : Preliminary findings. / Musselman, Dominique; Marzec, Ulla M.; Manatunga, Amita; Penna, Suzanne; Reemsnyder, Andrea; Knight, Bettina T.; Baron, Aimee; Hanson, Stephen R.; Nemeroff, Charles.

In: Archives of General Psychiatry, Vol. 57, No. 9, 19.09.2000, p. 875-882.

Research output: Contribution to journalArticle

Musselman, D, Marzec, UM, Manatunga, A, Penna, S, Reemsnyder, A, Knight, BT, Baron, A, Hanson, SR & Nemeroff, C 2000, 'Platelet reactivity in depressed patients treated with paroxetine: Preliminary findings', Archives of General Psychiatry, vol. 57, no. 9, pp. 875-882.
Musselman D, Marzec UM, Manatunga A, Penna S, Reemsnyder A, Knight BT et al. Platelet reactivity in depressed patients treated with paroxetine: Preliminary findings. Archives of General Psychiatry. 2000 Sep 19;57(9):875-882.
Musselman, Dominique ; Marzec, Ulla M. ; Manatunga, Amita ; Penna, Suzanne ; Reemsnyder, Andrea ; Knight, Bettina T. ; Baron, Aimee ; Hanson, Stephen R. ; Nemeroff, Charles. / Platelet reactivity in depressed patients treated with paroxetine : Preliminary findings. In: Archives of General Psychiatry. 2000 ; Vol. 57, No. 9. pp. 875-882.
@article{8f3ca88b9a4e458bb400d06acd0194d4,
title = "Platelet reactivity in depressed patients treated with paroxetine: Preliminary findings",
abstract = "Background: Alterations in platelet reactivity have been previously posited to underlie the increased vulnerability of patients with depression to ischemic heart disease (IHD). The present study sought to determine whether the increased platelet reactivity associated with major depression is reduced after antidepressant treatment. Methods: Patients diagnosed as having DSM-IV major depression (n = 15) (mean age, 37±7 years; range, 23-48 years) and 12 normal comparison subjects (mean age, 36±7; range, 23-48 years) were recruited. None of the controls or depressed group had evidence of IHD; 10 of 15 patients who were depressed had 1 or more traditional IHD risk factors. In vivo platelet activation, secretion, and dose-response aggregation of the controls and patients was measured after overnight bedrest under basal conditions, and after a mild exercise challenge. After 6 weeks of open-label treatment with the selective serotonin reuptake inhibitor paroxetine (20 mg/d), the patients with depression were readmitted and procedures of the first General Clinical Research Center admission repeated. Results: In comparison with the control group, the depressed group exhibited greater procoagulant activity as detected by increased platelet binding of the monoclonal antibodies anti-ligand-induced binding site and GA6, and increased plasma concentrations of platelet factor 4 under basal conditions. After paroxetine treatment, the patients with depression exhibited significant reductions in all 3 parameters. Conclusions: Normalization of platelet activation is associated with paroxetine treatment of patients with depression. Because this study design did not allow for the determination of whether this effect of paroxetine on platelet function is caused by a direct effect of the drug or placebo or, alternatively, because of recovery from depression, studies containing a placebo and/or psychotherapy treatment arm may resolve this issue.",
author = "Dominique Musselman and Marzec, {Ulla M.} and Amita Manatunga and Suzanne Penna and Andrea Reemsnyder and Knight, {Bettina T.} and Aimee Baron and Hanson, {Stephen R.} and Charles Nemeroff",
year = "2000",
month = "9",
day = "19",
language = "English",
volume = "57",
pages = "875--882",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Platelet reactivity in depressed patients treated with paroxetine

T2 - Preliminary findings

AU - Musselman, Dominique

AU - Marzec, Ulla M.

AU - Manatunga, Amita

AU - Penna, Suzanne

AU - Reemsnyder, Andrea

AU - Knight, Bettina T.

AU - Baron, Aimee

AU - Hanson, Stephen R.

AU - Nemeroff, Charles

PY - 2000/9/19

Y1 - 2000/9/19

N2 - Background: Alterations in platelet reactivity have been previously posited to underlie the increased vulnerability of patients with depression to ischemic heart disease (IHD). The present study sought to determine whether the increased platelet reactivity associated with major depression is reduced after antidepressant treatment. Methods: Patients diagnosed as having DSM-IV major depression (n = 15) (mean age, 37±7 years; range, 23-48 years) and 12 normal comparison subjects (mean age, 36±7; range, 23-48 years) were recruited. None of the controls or depressed group had evidence of IHD; 10 of 15 patients who were depressed had 1 or more traditional IHD risk factors. In vivo platelet activation, secretion, and dose-response aggregation of the controls and patients was measured after overnight bedrest under basal conditions, and after a mild exercise challenge. After 6 weeks of open-label treatment with the selective serotonin reuptake inhibitor paroxetine (20 mg/d), the patients with depression were readmitted and procedures of the first General Clinical Research Center admission repeated. Results: In comparison with the control group, the depressed group exhibited greater procoagulant activity as detected by increased platelet binding of the monoclonal antibodies anti-ligand-induced binding site and GA6, and increased plasma concentrations of platelet factor 4 under basal conditions. After paroxetine treatment, the patients with depression exhibited significant reductions in all 3 parameters. Conclusions: Normalization of platelet activation is associated with paroxetine treatment of patients with depression. Because this study design did not allow for the determination of whether this effect of paroxetine on platelet function is caused by a direct effect of the drug or placebo or, alternatively, because of recovery from depression, studies containing a placebo and/or psychotherapy treatment arm may resolve this issue.

AB - Background: Alterations in platelet reactivity have been previously posited to underlie the increased vulnerability of patients with depression to ischemic heart disease (IHD). The present study sought to determine whether the increased platelet reactivity associated with major depression is reduced after antidepressant treatment. Methods: Patients diagnosed as having DSM-IV major depression (n = 15) (mean age, 37±7 years; range, 23-48 years) and 12 normal comparison subjects (mean age, 36±7; range, 23-48 years) were recruited. None of the controls or depressed group had evidence of IHD; 10 of 15 patients who were depressed had 1 or more traditional IHD risk factors. In vivo platelet activation, secretion, and dose-response aggregation of the controls and patients was measured after overnight bedrest under basal conditions, and after a mild exercise challenge. After 6 weeks of open-label treatment with the selective serotonin reuptake inhibitor paroxetine (20 mg/d), the patients with depression were readmitted and procedures of the first General Clinical Research Center admission repeated. Results: In comparison with the control group, the depressed group exhibited greater procoagulant activity as detected by increased platelet binding of the monoclonal antibodies anti-ligand-induced binding site and GA6, and increased plasma concentrations of platelet factor 4 under basal conditions. After paroxetine treatment, the patients with depression exhibited significant reductions in all 3 parameters. Conclusions: Normalization of platelet activation is associated with paroxetine treatment of patients with depression. Because this study design did not allow for the determination of whether this effect of paroxetine on platelet function is caused by a direct effect of the drug or placebo or, alternatively, because of recovery from depression, studies containing a placebo and/or psychotherapy treatment arm may resolve this issue.

UR - http://www.scopus.com/inward/record.url?scp=0033857466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033857466&partnerID=8YFLogxK

M3 - Article

C2 - 10986551

AN - SCOPUS:0033857466

VL - 57

SP - 875

EP - 882

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 9

ER -